SEC Filing Summary: Cara Therapeutics, Inc. (8-K)
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cara Therapeutics, Inc. on August 23, 2021. The registrant is a Delaware corporation with principal executive offices in Stamford, Connecticut. The company is an emerging growth company and its common stock trades on The Nasdaq Stock Market LLC under the symbol CARA.
Key Financial Metrics
This filing is a current report regarding a specific corporate event and does not provide financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The filing text does not contain numerical financial data for the period.
Material Changes and Events
- Regulatory Approval: On August 23, 2021, the U.S. Food and Drug Administration (FDA) approved the company's New Drug Application (NDA) for KORSUVA injection.
- Indication: The approved treatment is for moderate-to-severe pruritus (itching) in hemodialysis patients.
- Disclosure: This event was reported under Item 8.01 (Other Information) and a press release is attached as Exhibit 99.1.
Guidance, Outlook, and Risks
The filing text does not provide specific financial guidance, forward-looking revenue projections, or a detailed discussion of risks and contingencies beyond the announcement of the FDA approval. Management commentary is limited to the issuance of the press release regarding the regulatory milestone.
Key Facts for Investor Verification
- Verify the commercial launch timeline and pricing strategy for KORSUVA following FDA approval.
- Review the attached press release (Exhibit 99.1) for specific details on the approval scope and any conditions.
- Check subsequent filings (e.g., 10-Q or 10-K) for the financial impact of this approval on revenue and cash burn.
- Confirm the company's status as an emerging growth company and any related accounting election impacts.